183 related articles for article (PubMed ID: 34499221)
21. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
Du Y; Wang Q; Zhang X; Wang X; Qin C; Sheng Z; Yin H; Jiang C; Li J; Xu T
J Exp Clin Cancer Res; 2017 May; 36(1):66. PubMed ID: 28494778
[TBL] [Abstract][Full Text] [Related]
22. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
23. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
[TBL] [Abstract][Full Text] [Related]
25. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
26. Expression and Prognostic Significance of
Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwińska-Jewsiewicka A; Wierzbicki PW; Kmieć Z
Anticancer Res; 2017 Jun; 37(6):2927-2937. PubMed ID: 28551630
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis identifies NF-κB as a therapeutic target in renal cancer.
Peri S; Devarajan K; Yang DH; Knudson AG; Balachandran S
PLoS One; 2013; 8(10):e76746. PubMed ID: 24116146
[TBL] [Abstract][Full Text] [Related]
28. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
29.
Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
[TBL] [Abstract][Full Text] [Related]
30. Identification of a glycolysis-related lncRNA prognostic signature for clear cell renal cell carcinoma.
Ma W; Zhong M; Liu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34402862
[TBL] [Abstract][Full Text] [Related]
31. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.
Malouf GG; Zhang J; Yuan Y; Compérat E; Rouprêt M; Cussenot O; Chen Y; Thompson EJ; Tannir NM; Weinstein JN; Valero V; Khayat D; Spano JP; Su X
Mol Oncol; 2015 Jan; 9(1):32-43. PubMed ID: 25126716
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
34. RBM4 inhibits the growth of clear cell renal cell carcinoma by enhancing the stability of p53 mRNA.
Jian W; Xue W; Wang T; Yu Y; Cai L; Meng Y; Xia Z; Zhang C
Mol Carcinog; 2023 Apr; 62(4):464-478. PubMed ID: 36585906
[TBL] [Abstract][Full Text] [Related]
35. Ubiquitin E3 ligase UHRF1 regulates p53 ubiquitination and p53-dependent cell apoptosis in clear cell Renal Cell Carcinoma.
Ma J; Peng J; Mo R; Ma S; Wang J; Zang L; Li W; Fan J
Biochem Biophys Res Commun; 2015 Aug; 464(1):147-53. PubMed ID: 26102039
[TBL] [Abstract][Full Text] [Related]
36. Procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1, 2, and 3 are potential prognostic indicators in patients with clear cell renal cell carcinoma.
Xu WH; Xu Y; Wang J; Tian X; Wu J; Wan FN; Wang HK; Qu YY; Zhang HL; Ye DW
Aging (Albany NY); 2019 Aug; 11(16):6503-6521. PubMed ID: 31446433
[TBL] [Abstract][Full Text] [Related]
37. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
[TBL] [Abstract][Full Text] [Related]
38. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
[TBL] [Abstract][Full Text] [Related]
39. Pan-cancer analysis and experiments with cell lines reveal that the slightly elevated expression of DLGAP5 is involved in clear cell renal cell carcinoma progression.
Feng Y; Li F; Yan J; Guo X; Wang F; Shi H; Du J; Zhang H; Gao Y; Li D; Yao Y; Hu W; Han J; Zhang M; Ding R; Wang X; Huang C; Zhang J
Life Sci; 2021 Dec; 287():120056. PubMed ID: 34687756
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
